Discovery of Biological Signatures for Cruciferous Vegetable Intake (Single Serving)
NCT ID: NCT04641026
Last Updated: 2025-03-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
83 participants
INTERVENTIONAL
2021-02-22
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Green Vegetables and Women's Health
NCT01726127
Daily Consumption of Well-Cooked Broccoli May Affect Glucosinolate Metabolites and Inflammatory Biomarkers
NCT03013465
Cross-Over Broccoli Sprouts Trial
NCT01008826
Intervention Study on Iodine Biofortification Vegetables ( Nutri-I-Food
NCT05011968
Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation
NCT01265953
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Broccoli sprouts
Subjects will consume one serving (about 1 cup) of broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
Broccoli sprouts
Subjects will consume one serving (about 1 cup) of broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
Deuterium oxide-labeled broccoli sprouts
Subjects will consume one serving (about 1 cup) of deuterium oxide-labeled broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
Deuterium oxide-labelled broccoli sprouts
Subjects will consume one serving (about 1 cup) of deuterium oxide-labelled broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
Alfalfa sprouts
Subjects will consume one serving (about 1 cup) of alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
Alfalfa sprouts
Subjects will consume one serving (about 1 cup) of alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
Deuterium oxide-labeled alfalfa sprouts
Subjects will consume one serving (about 1 cup) of deuterium oxide-labeled alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
Deuterium oxide-labelled alfalfa sprouts
Subjects will consume one serving (about 1 cup) of deuterium oxide-labelled alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Broccoli sprouts
Subjects will consume one serving (about 1 cup) of broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
Deuterium oxide-labelled broccoli sprouts
Subjects will consume one serving (about 1 cup) of deuterium oxide-labelled broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
Alfalfa sprouts
Subjects will consume one serving (about 1 cup) of alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
Deuterium oxide-labelled alfalfa sprouts
Subjects will consume one serving (about 1 cup) of deuterium oxide-labelled alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing to stop taking herbal and phytochemical (plant-based extract or phytochemical) supplements for 1 week prior to and during the study
* Willing to stop cruciferous vegetable and probiotic supplement, food and beverage intake 1 week prior to and during the study
* Willing to complete a 10-day food diary during the study
* Must be able to give written informed consent
Exclusion Criteria
* Tobacco use, including e-cigarettes, or smoking of any substance (e.g. cannabis) in the past three months
* Pregnancy, breastfeeding, or planning to become pregnant before completing the study
* Engaging in vigorous exercise more than 7 hours per week
* Have a significant acute or chronic illness such as cardiovascular disease, kidney or liver disease, diabetes, thyroid disorder, or radiation or chemotherapy treatment for cancer within the past five years.
* Use of medications to control cholesterol (e.g. statins, cholestyramine) or fat absorption (e.g. orlistat)
* Have had bariatric surgery (e.g. gastric bypass, gastric banding, sleeve gastrectomy, etc.), other gastrointestinal procedure (e.g. cholecystectomy) or disorders (e.g. Crohn's disease, celiac disease, ulcerative colitis)
* Use of oral antibiotic medication within the 6 months
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
United States Department of Agriculture (USDA)
FED
Oregon State University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Emily Ho
Endowed Chair and Director, Linus Pauling Institute Professor, College of Public Health and Human Sciences
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emily Ho, PhD
Role: PRINCIPAL_INVESTIGATOR
Oregon State University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oregon State University
Corvallis, Oregon, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-67001-31214
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
LPI-8343
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.